Optimal use of lenvatinib in the treatment of advanced thyroid cancer

The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth f...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shunji, Kiyota, Naomi, Tahara, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460646/
https://www.ncbi.nlm.nih.gov/pubmed/31093354
http://dx.doi.org/10.1186/s41199-017-0026-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460646/
https://www.ncbi.nlm.nih.gov/pubmed/31093354
http://dx.doi.org/10.1186/s41199-017-0026-0

Ejemplares similares